sibutramine has been researched along with fenfluramine in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lean, ME | 1 |
| Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M | 1 |
| Heal, DJ; Hutchins, LJ; Jackson, HC; Mazurkiewicz, SE; Needham, AM | 1 |
| Auerbach, SB; Gundlah, C; Heal, DJ; Martin, KF | 1 |
| Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS | 1 |
| Aspley, S; Cheetham, SC; Heal, DJ; Jackson, HC; Martin, KF; Prow, MR | 1 |
| Birkeland, KI; Tonstad, S | 1 |
| Ryan, DH | 1 |
| Bickerdike, MJ; Dourish, CT; Vickers, SP | 1 |
| Dill, PL; Ericsson, M; Foreyt, JP; Haddock, CK; Poston, WS | 1 |
| Jones, SL; Miller, DK; Wellman, PJ | 1 |
| Cheng, D; Chi, CL; Gan, J; Han, S; Largent, BL; O'Tanyi, EJ; Rohrbach, KW; Taub, R; Zhang, H | 1 |
| Chan, AY; Lai, CK; Mak, TW; Ng, SW; Poon, WT; Yuen, YP | 1 |
| Choi, S; Fernstrom, JD | 1 |
| Bernardi, G; Federici, M; Ledonne, A; Mercuri, NB; Sebastianelli, L | 1 |
| Kaplan, LM | 1 |
| Astrup, A | 1 |
| Gao, B; Shi, Y; Sun, A; Sun, C | 1 |
| Fujioka, M; Mikami, E; Miyamoto, K; Sumioka, S; Yamamoto, S | 1 |
| Bedros, JR; Medvegy, M; Pados, G; Simonyi, G | 1 |
| Chen, B; Ding, L; Guo, B; Sun, W; Wang, H; Wu, Y; Zhao, Y | 1 |
| Guo, L; Jin, R; Li, L; Li, W; Shen, Q | 1 |
11 review(s) available for sibutramine and fenfluramine
| Article | Year |
|---|---|
Sibutramine--a review of clinical efficacy.
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Body Weight; Cardiovascular Physiological Phenomena; Cardiovascular System; Clinical Trials as Topic; Cyclobutanes; Dose-Response Relationship, Drug; Fenfluramine; Humans; Obesity; Weight Loss | 1997 |
The pharmacologic approach to the treatment of obesity.
Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabolism; Fenfluramine; Fluoxetine; Humans; Obesity | 1997 |
Challenges in obesity management.
Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobutanes; Diethylpropion; Ephedrine; Fenfluramine; Fluoxetine; Humans; Lactones; Leptin; Lipase; Obesity; Orlistat; Phentermine; Proteins; Sertraline | 1998 |
Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
Topics: Animals; Biogenic Monoamines; Cyclobutanes; Dextroamphetamine; Energy Metabolism; Fenfluramine; Humans; Hypertension, Pulmonary; Obesity; Selective Serotonin Reuptake Inhibitors | 1998 |
[The obesity epidemics--do diet pills have a place in the treatment?].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fenfluramine; Humans; Lactones; Leptin; Obesity; Obesity, Morbid; Orlistat; Phentermine; Selective Serotonin Reuptake Inhibitors; Weight Loss | 2000 |
Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Dexfenfluramine; Dextroamphetamine; Fenfluramine; Heart Valve Diseases; Humans; Obesity; Phenylpropanolamine; Serotonin Agents; Weight Loss | 2000 |
5-HT2C receptor modulation and the treatment of obesity.
Topics: Animals; Appetite Depressants; Cyclobutanes; Disease Models, Animal; Fenfluramine; Humans; Obesity; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors | 1999 |
Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.
Topics: Amphetamines; Anti-Obesity Agents; Benzphetamine; Cyclobutanes; Fenfluramine; Humans; Obesity; Randomized Controlled Trials as Topic | 2002 |
The development of tolerance to drugs that suppress food intake.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Drug Tolerance; Eating; Fenfluramine; Humans; Leptin; Obesity; Rats; Time Factors; Weight Loss | 2008 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; Ephedrine; Fenfluramine; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Weight Gain; Weight Loss | 2010 |
[The pharmacological treatment of obesity: past, present and future].
Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones | 2012 |
12 other study(ies) available for sibutramine and fenfluramine
| Article | Year |
|---|---|
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptake Inhibitors; Obesity; Rats; Rats, Sprague-Dawley; Venlafaxine Hydrochloride | 1997 |
In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Cyclobutanes; Fenfluramine; Fluoxetine; Male; Microdialysis; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin | 1997 |
Studies confirm link between fen-phen and heart-valve disease.
Topics: Appetite Depressants; Cyclobutanes; Dexfenfluramine; Drug Combinations; Fenfluramine; Heart Valve Diseases; Humans; Obesity; Phentermine | 1998 |
Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Appetite Depressants; Body Weight; Cyclobutanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Eating; Fenfluramine; Fluoxetine; Male; Norepinephrine; Phentermine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2003 |
Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents.
Topics: 4-Butyrolactone; Animals; Appetite Depressants; Behavior, Animal; Blotting, Northern; Cyclobutanes; Dose-Response Relationship, Drug; Fatty Acid Synthases; Fenfluramine; Food Deprivation; Hypothalamus; Immunoblotting; Injections, Intraperitoneal; Injections, Intraventricular; Kinetics; Male; Phentermine; Random Allocation; Rats; Rats, Inbred F344; RNA; Time Factors | 2005 |
Adulteration of over-the-counter slimming products with pharmaceutical analogue--an emerging threat.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Chemistry, Pharmaceutical; Cyclobutanes; Drug and Narcotic Control; Drug Contamination; Female; Fenfluramine; Hong Kong; Hospitalization; Humans; Liver; Male; Middle Aged; Nonprescription Drugs; Selective Serotonin Reuptake Inhibitors; Thyroid Hormones; Toxicity Tests; Weight Loss | 2007 |
The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells.
Topics: Animals; Appetite Depressants; Baclofen; Cyclobutanes; Dopamine; Fenfluramine; GABA-A Receptor Agonists; GABA-B Receptor Agonists; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Male; Mesencephalon; Neurons; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1B; Receptors, GABA-A; Receptors, GABA-B; Serotonin 5-HT1 Receptor Agonists; Substantia Nigra; Ventral Tegmental Area | 2009 |
Drug management of obesity--efficacy versus safety.
Topics: Anti-Obesity Agents; Benzazepines; Contraindications; Cyclobutanes; Drug Approval; Fenfluramine; Humans; Obesity; Overweight; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; United States; United States Food and Drug Administration; Weight Loss | 2010 |
Development of a liquid chromatography tandem mass spectrometry method for simultaneous determination of eight adulterants in slimming functional foods.
Topics: Anthraquinones; Chromatography, Liquid; Clopamide; Cyclobutanes; Diet, Reducing; Emodin; Ephedrine; Fenfluramine; Food Contamination; Functional Food; Linear Models; Methanol; Phenylpropanolamine; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Temperature | 2011 |
Study on detection of drugs in slimming health foods using GC-MS/MS.
Topics: Cyclobutanes; Drug Approval; Fenfluramine; Food, Organic; Gas Chromatography-Mass Spectrometry; Legislation, Drug; Mazindol; Phenolphthalein; Tandem Mass Spectrometry | 2011 |
Rapid screening of illicit additives in weight loss dietary supplements with desorption corona beam ionisation (DCBI) mass spectrometry.
Topics: Anti-Obesity Agents; Appetite Depressants; China; Chromatography, High Pressure Liquid; Cyclobutanes; Dietary Supplements; Fenfluramine; Food Contamination; Food Inspection; Indicators and Reagents; Legislation, Food; Mass Spectrometry; Phenolphthalein; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors | 2012 |
A graphene tip coupled with liquid chromatography tandem mass spectrometry for the determination of four synthetic adulterants in slimming supplements.
Topics: Appetite Depressants; Bumetanide; Chromatography, Liquid; Cyclobutanes; Dietary Supplements; Fenfluramine; Graphite; Limit of Detection; Phenolphthalein; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry | 2017 |